Reg Peptide Beta Cell Regeneration Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly type 1 and 2, lack effective methods for restoring and maintaining beta cell mass, leading to inadequate insulin production and associated complications.
Innovation Solution
Identification of specific bioactive peptide sequences within the human Reg1a, Reg1b, Reg3a, and Reg4 proteins that directly bind to the Reg Receptor on extra-islet exocrine tissue, stimulating the generation of new pancreatic beta cells through the use of peptidomimetics and stimulating antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diabetes treatments are used, then blood glucose levels can be controlled, but beta cell mass cannot be restored
Solution Approach 1:
The patent applies preliminary action by administering Reg peptides or stimulating antibodies before complete beta cell loss occurs, or at the early stages of diabetes, to stimulate endogenous beta cell regeneration. This proactive approach aims to restore beta cell mass before the disease progresses to a point where no endogenous cells remain to be stimulated.
Solution Approach 2:
The patent uses Reg peptides and stimulating antibodies as intermediary substances that mediate between the administered therapy and the target beta cells or progenitor cells. These intermediaries bind to specific receptors on pancreatic cells to trigger signaling cascades that promote beta cell proliferation and regeneration, bridging the gap between external treatment and internal cellular response.
2Reliability
If exogenous insulin is administered, then blood glucose control is achieved, but endogenous insulin production remains insufficient
Solution Approach 1:
The patent employs self-service by stimulating the patient's own pancreatic cells to produce endogenous insulin through Reg peptide or antibody administration. This approach enables the body's own cells to regenerate and resume insulin production, reducing or eliminating the need for lifelong exogenous insulin dependence and allowing patients to maintain glucose control through their own physiological systems.
3Ease of operation
If conventional diabetes management is used, then symptoms can be managed, but beta cell deficiency cannot be reversed
Solution Approach 1:
The patent extracts and utilizes the specific bioactive peptide sequences from the Reg family proteins (Reg1a, Reg1b, Reg3a, Reg4) that are responsible for stimulating beta cell regeneration. By isolating and administering these specific peptide sequences or antibodies against their receptors, the therapy targets the underlying cause of beta cell deficiency rather than merely managing symptoms, enabling reversal of the deficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution enables the accelerated generation of new beta cells, potentially reversing diabetes by enhancing insulin production and improving glucose metabolism, with applications in treating type 1 and 2 diabetes, pre-diabetes, and related conditions.
Implementation Method 1
Identification of specific bioactive peptide sequences within the human Reg1a, Reg1b, Reg3a, and Reg4 proteins that directly bind to the Reg Receptor on extra-islet exocrine tissue
Data Source
AI summary
The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue. This invention identifies a specific binding region of the Reg Receptor from which peptidomimetics and stimulating antibodies have been developed for the generation of new beta cells which may be administered directly to patients with said conditions including type 1 diabetes, type 2 diabetes, PreDiabetes and other conditions of beta cell deficiency, and provides specific methodology for protecting new beta cells generated for usage in type 1 diabetes and Latent Autoimmune Diabetes of Adulthood. This invention also provides for ex-vivo generation and delivery of beta cells utilizing the inventions described within.